Edgewise Therapeutics (EWTX)
(Delayed Data from NSDQ)
$15.53 USD
+1.64 (11.81%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $15.60 +0.07 (0.45%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Fundamental Charts
About Return on Equity (TTM)
Edgewise Therapeutics, Inc.'s return on equity, or ROE, is -30.65% compared to the ROE of the Medical - Biomedical and Genetics industry of -67.20%. While this shows that EWTX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
EWTX 15.53 +1.64(11.81%)
Will EWTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for EWTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EWTX
Wall Street Analysts Think Edgewise Therapeutics (EWTX) Could Surge 182%: Read This Before Placing a Bet
Wall Street Analysts Believe Edgewise Therapeutics (EWTX) Could Rally 172.96%: Here's is How to Trade
EWTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy
Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb
Other News for EWTX
Is EWTX building bearish momentum? Fell Below 50 Day Moving Average shows up after sinking 1.21%
Orbimed Advisors LLC Adjusts Holdings in PMV Pharmaceuticals Inc
EWTX Crossed Above 50 Day Moving Average on September 16
EWTX Fell Below 50 Day Moving Average on September 15
Tracking Baker Brothers Portfolio - Q2 2025 Update